VIDEO: Novel treatments for relapsed refractory multiple myeloma highlighted at ASH
NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses research regarding novel relapsed refractory multiple myeloma treatments presented at the ASH Annual Meeting and…
Source/Disclosures
Source:
Healio Interviews
Disclosures:
Banerjee reports receiving research funding from Pack Health, serving in consulting or advisory roles for Bristol-Myers Squibb/Celgene, Genentech/Roche, Guidepoint Global, Janssen Oncology, Sanofi Pasteur and SparkCures, and receiving honoraria from Curio Science.
Source/Disclosures
Source:
Healio Interviews
Disclosures:
Banerjee reports receiving research funding from Pack Health, serving in consulting or advisory roles for Bristol-Myers Squibb/Celgene, Genentech/Roche, Guidepoint Global, Janssen Oncology, Sanofi Pasteur and SparkCures, and receiving honoraria from Curio Science.
ADD TOPIC TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact EMAIL.
NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses research regarding novel relapsed refractory multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.
One study highlighted by Banerjee, an assistant professor at the University of Washington, explored dosing of mezigdomide and dexamethasone in patients with triple-class refractory multiple myeloma. The overall response rate was found to be 40.6% in all patients, but importantly, in those who had received prior anti-B-cell maturation antigen therapy, the overall response rate was 50%, Banerjee said.
"As ide-cel and CAR-T therapy move into earlier lines of therapy, as bispecifics move into earlier lines of therapy — the vast majority of them targeting BCMA — we're going to have more and more patients who are BCMA refractory or at least BCMA exposed,' Banerjee said. 'Some data will be quadruple-class refractory for patients who have also received BCMA therapies, and for those patients, the fact that an all-oral doublet regimen achieves a 50% overall response rate is phenomenal."
Banerjee also highlighted data from a multicenter phase 1 trial investigating CC98633/BMS-986354 in patients with relapsed refractory myeloma, which showcased a 95% ORR across all dose levels.
References:
Megala Costa LJ, et al. Abstract 566. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Richardson PG, et al. Abstract 568. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.